Vectibix, generically known as panitumumab, is a targeted monoclonal antibody therapy used in the treatment of metastatic colorectal cancer. Specifically, it is designed to target and inhibit the epidermal growth factor receptor (EGFR), a protein found on the surface of some cancer cells that helps them grow and divide. By blocking EGFR, Vectibix can help slow down or stop the growth of cancer cells. It is typically prescribed for patients whose tumors express the EGFR and do not have mutations in the RAS gene (KRAS or NRAS), as these mutations can render the treatment ineffective. Vectibix is administered through intravenous infusion and is often used in combination with other chemotherapy drugs to enhance its effectiveness. However, it is associated with certain side effects, such as skin rash, which requires careful management and monitoring by healthcare professionals.